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ANALISA PERKAITAN GENETIK BAHAGIAN GEN TGFB1 DAN SMAD4 
DENGAN PENYAKIT KELOID DALAM POPULASI MELAYU 
 
ABSTRAK 
 
Pembentukkan keloid adalah sebabkan oleh  faktor persekitaran and genetik. Dua 
jenis gen iaitu TGFβ1 dan SMAD4  yang terletak pada signal yang sama dan sangat 
tinggi di ekpresi di dalam fibroblast sel keloid. Kajian ini bertujuan 
untuk menyiasat kaitan di antara  varian  TGFβ1 dan SMAD4 gen 
menggunakan kaedah genotyping PCR-RFLP.  Frekuensi alel, genotip dan haplotaip 
jenis ini berbanding antara 100 kes keloid dan 100 kawalan sihat biasa. Tiada kaitan 
signifikan di temui di dalam kes-kawalan di kalangan populasi Melayu bagi  allel dan 
genetik variasi  untuk TGFβ1. Manakala untuk TGFβ1 haplotaip keputusan yang 
berbeza di tunjukkan, iaitu penyumbangan kepada risiko memperolehi  keloid. C-C 
haplotaip yang mengandungi c.29C>T dan -509 T>C varian kerap di temui di 
kalangan kes keloid (p - nilai yang telah di ubah = 0.037, OR = 2.07, 95% CI = 0.87-
4.93), menunjukkan 4.5 kali berisiko untuk memperolehi keloid. AG genotaip untuk 
SMAD4 iaitu c5131A>G varian menunjukkan statistik signifikan (P-nilai = 0.0573, 
OR = 1.75, 95% CI = 0.99-3.13). Di samping itu juga, C-C haplotaip untuk  varian 
TGFβ1 menunjukkan peningkatan risiko ke arah keloid apabila bergabung dengan 
SMAD4 c.5131A>G varian. Ini menunjukkan interaksi di antara gen kepada 
perkembangan keloid. Varian berlaku samaada di peringkat ekpresi  ataupun  di 
dalam ketidakseimbangan hubungan dan bergabung dengan faktor persekitaran boleh 
menyumbang kepada keaadaan tersebut. Setakat ini, hanya satu laporan di 
berdasarkan populasi orang berkulit putih yang menunjukkan hubung kait TGFβ1 dan 
xx 
 
keloid, manakala tiada laporan di buat bagi SMAD4. Oleh sebab itu, kajian ini 
merupakan kajian pertama yang menunjukkan kaitan yang positif antara TGFβ1 dan 
SMAD4 varian dengan keloid di kalangan populasi Melayu.  
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ANALYSIS OF GENETIC ASSOCIATION OF TGFΒ1 AND SMAD4 GENES 
WITH KELOID IN MALAY POPULATION 
 
ABSTRACT 
 
 
Keloid is a complex condition with environmental and genetic risk-contributing 
factors. Two candidate genes, TGFβ1 and SMAD4, located in the same signaling 
pathway are highly expressed in the keloid fibroblast cells. The present study 
investigated the association between variants of TGFβ1 and SMAD4 genes using 
PCR-RFLP genotyping method. Allele, genotype and haplotype frequencies of these 
variants were compared between 100 keloid cases and 100 normal healthy controls. 
No statistical significant difference was found between alleles and genotypes of 
TGFβ1 variants in the current case-control study in a Malay population, while TGFβ1 
haplotypes in contrast showed a strong association with the risk of keloid. The C-C 
haplotype, composed of both c.29C>T and -509 T>C variants was observed more 
frequently among cases (Corrected p-value = 0.037, OR = 2.07, 95% CI = 0.87-4.93), 
showing a 4.5-fold increased risk for keloid. The AG genotype of the SMAD4 
c.5131A>G variant showed a statistically significant trend (P-value = 0.0573, OR = 
1.75, 95% CI = 0.99-3.13). The C-C haplotype of TGFβ1 variants showed an 
increased risk when combined with both alleles of the SMAD4 c.5131A>G variant, 
indicating possible interaction of these genes in keloid development. Either of these 
variants is most probably causative at the expression level or is in linkage 
disequilibrium with other causative variants in a complex pattern together with the 
environmental factors that contribute to the condition. There is only one documented 
xxii 
 
report on a relationship between TGFβ1 and keloid with no association in the 
Caucasian population, while there has been no report for SMAD4. Therefore, the 
present study is the first of its kind showing a strong positive association between 
TGFβ1 and SMAD4 variants and keloids in the Malay population. 
 
 
1CHAPTER ONE
INTRODUCTION
1.1 Background of the study
The skin is the largest organ that supports the whole body from mechanical
impact, thermal and chemical impact, UV radiation and water loss. In
addition, the skin protects the body against microorganisms by its acidic pH
value. One of the largest defense mechanisms that the body has is through the
epidermis and dermis.
At microscopic level, the skin is composed of two main layers; epidermis and
dermis. Epidermis contains several layers namely the basal cell layer, the
spinous cell layer, the granular cell layer and the stratum corneum. The cells in
the epidermis are called keratinocytes. The dermis with a variable amount of
fat, collagen and elastic fibers provides strength and flexibility of the skin.
The skin can be affected by several conditions, but the most common skin
diseases has been categorized into eight common types: rashes, bacterial
infections, fungal infections, parasitic infections, pigmentation disorders,
tumors and cancers and trauma (Kelly and Taylor, 2009).
Keloid and hypertrophic scars are benign proliferative diseases that caused by
overproducing of collagen. In keloid scarring which also known as keloid
2disease (KD), the scar may grow beyond the boundaries of the original injury
that can occur even after a minor skin trauma. Hypertrophic scar in contrast is
a cutaneous lesion that characterized by excess scar tissue and remains within
the boundaries of the original injury. Hypertrophic scars are usually red, pink
or purple in color, hypersensitive to touch and may itch or be generally
painful. Hypertrophic scars usually occur soon after injury and improve over
the time in contrast to the keloid scars. Keloid scars may occur few months
after injury (Wolfram et al., 2009).
In addition, keloid characterizes by a collection of atypical fibroblasts with
excessive deposition of extracellular matrix components, especially collagen,
fibronectin, elastin and proteoglycans. Keloids are benign hyperproliferative
growths of dermal fibroblasts (Kelly, 2004). However, most of cases occur
sporadically, but familial cases are common as well.
There are many risk factors involved in the development of this disease.
Keloid is known with alterations in growth factors, collagen turnover and
tension alignment. Genetics and environmental risk factors contribute to the
etiology of this disease. Trauma, foreign-body reactions, infections and
endocrine dysfunctions have been suggested as environmental risk factors of
keloids (Russell et al., 1988). In addition, keloid scars can be caused by
surgery, an accident, by acne or, sometimes, from body piercings. Both sexes
are susceptible to keloid with an equal proportion (Shaffer et al., 2002, Kuflik,
1994, Child et al., 1999).
3Keloid can develop at every age but higher incidence is noticed between 10
and 30 years. Average age of first keloid diagnosis has been reported 22.3
years for women and 22.8 years for men (Cosman et al., 1996). It has been
suggested that hormones contribute in the keloid development. This evidence
has been supported by data that showing an elevated androgen receptor level
in the clinically active keloid tissue (Schierle et al., 1997). A higher incidence
of keloid has been reported during pregnancy and puberty (Oluwasanmi,
1974). Alterations in the hormone profile and increased neo-angiogenesis
during pregnancy has been suggested as possible explanation.
The incidence of keloid varies among different races. In general, it is more
common among peoples with a black skin compared with those with a white
skin (McDonald, 1988, Fong et al., 1999). Higher incidence of keloid in black
peoples has been attributed to the thick and more seborrhoeic skin of them.
The incidence of keloids in Caucasians in the United Kingdom is reported to
be <1% (Bloom, 1956), while the incidence in Blacks and Hispanics varies
from 4.5 to 16% (Oluwasanmi, 1974). The higher rate for earlobe keloids after
piercing may be responsible for a slight female predominance (Kelly, 2004).
Keloid is genetically heterogeneous and different genes may be involved in
different populations (Yan et al., 2007b, Brown et al., 2008a, Nassiri et al.,
2009).
There is no single therapy procedure for keloid as yet. Treatment for this
disease can be difficult, and is not usually successful. The common treatment
procedures in keloid include surgery (Brown et al., 1990, Salasche and
4Grabski, 1983), pressure (Urioste et al., 1999), topical silicone gel (Slemp and
Kirschner, 2006), radiation (DeBeurmann and Gougerot, 1906), laser therapy
(Alster, 1997), corticosteroids (Golladay, 1988), Imiquimod 5% cream
(Berman and Villa, 2003) and onion extract (Zurada et al., 2006).
1.2 Problem statement
The increased familial aggregation, increased prevalence in certain races and
increased concordance in identical twins provide a strong genetic
predisposition to etiology of keloid. In addition, syndromic forms of keloid
support the hypothesis of a genetic background for keloid (Hendrix and Greer,
1996, Goeminne, 1968). It seems that development of keloid controls by
several loci under both autosomal recessive (Omo-Dare, 1975) and autosomal
dominant mode of inheritance (Marneros et al., 2001, Shaffer et al., 2002).
Several candidate loci have been identified in association with keloid
including 15q22, 18q21.1, P53, HLA-DRB1, 19q13.1, 2q23, 7p11, Xq28,
TGF-β, SMAD and Caspase family genes (Zuffardi and Fraccaro, 1982,
Marneros et al., 2004, Yan et al., 2007b, Liu et al., 2008b, Brown et al.,
2008b). Lu et al., (2008) described a positive association of HLA-DQA1 and
DQB1 alleles and haplotypes with keloids and Rossi and Bozzi (1989)
proposed an association with the HLA-types, HLA-DR5 and HLA DQw3.
Transforming growth factor Beta (TGFβ) has previously been implicated in
keloid pathogenesis (Bayat et al., 2002, Bayat et al., 2003b, Bayat et al.,
2005a, Bayat et al., 2005b) and the high expression of TGFβ1 has been
associated with keloid formation by several investigators (Peltonen et al.,
51991, Niessen et al., 1999, Chin et al., 2001). Therefore, the basis for keloid
formation has not been fully clear and though different genes are said to be
involved in the formation of keloids, the role of these in keloid formation has
not been clearly established.
1.3 Justification of the study
The role of genetics in development of keloids has been accepted through
various studies in different populations using expression analysis, linkage
analysis and case-control association studies. Keloid is a heterogeneous
disease at clinical and molecular level, as several genes and or loci has been
recognized as candidate in its development. Therefore, the aim of this study is
to investigate the role of two candidate regions namely TGFβ and Mothers
against decapentaplegic homolog4 (SMAD4) in cases with keloid in
comparison with controls. In both these regions, some strong candidate genes
for Keloids are located which suggests interaction in the same molecular
pathway. TGFβ1 (OMIM #190180) gene, one of the candidate genes for
keloid, is located on 19q13.1 chromosomal region. TGFβ1, TGFβ2 (OMIM
#190220), and TGFβ3 (OMIM #190230) genes act through the same receptor
signaling systems (Massague, 2000).
Transforming growth factor beta (TGFβ) plays an important role in wound
healing and many fibrotic diseases including cirrhosis, chronic hepatitis,
glomerulonephritis, scleroderma and pulmonary fibrosis (Border and Noble,
1994, Massague, 2000). Many biological functions have been suggested for
6TGF-β family genes including; regulation of cell proliferation, migration,
differentiation and development, tissue turnover and repair (Massague, 2000).
TGFβ1 and TGFβ2 are supposed to be the most important cytokines
responsible for keloid scarring (Niessen et al., 1999). The TGFβ1 gene
expression plays a critical role in development of fibrosis in keloid (Peltonen
et al., 1991).
Genetic linkage was found between 18q21.1 and keloid disease in a Chinese
population (Yan et al., 2007b). The SMAD 2, 4 and 7 genes are located in this
region and these genes are candidate in the development of keloids. The
importance of SMAD genes and their role in fibrotic disorders has been well
documented. The signals from TGFβ family members transmit via cell surface
receptors to the SMAD proteins. SMAD proteins act as transducer and transmit
the signals to nucleus (Flanders, 2004). Overall, there is close interaction
between TGFβ and SMAD family genes in the development of keloid scarring.
71.4 Objectives of the study
1.4.1 General objective
1. To determine the association between TGFβ1 and SMAD4 Genes with
keloid   scarring
1.4.2 Specific objectives
1. To determine the association between the SNPs c.29C>T and -509T>C of
TGFβ1 Gene and Keloid in Malay population in comparison with control
group.
2. To determine the association between the SNPs c.686T>G and c.5131A>G
of SMAD4 Gene and Keloid in Malay population in comparison with control
group.
3. To determine the interaction between these SNPs of TGFβ1 and SMAD4
Genes in patients with Keloid
1.5 Research hypothesis
Genetic variants in the TGFβ1and SMAD4 Genes are involved in the etiology
of Keloid formation in Malay population.
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REVIEW OF LITERATURE
2.1 Skin structure and function
Skin is the largest organ in body with several functions in which protection
against environmental factors and controlling the body’s fluid are the most
important role. Skin contains three structural layers; epidermis, the dermis and
subcutis (Figure 2.1). Skin is a dynamic organ in which dead outer layer cells
are continuously replaced by new cells that originate from basal layer.
Epidermis is the outer layer of skin that is relatively thin and tough. Epidermis
itself contains three sub-layer including stratum corneum (horny layer),
keratinocytes (squamous cells) and basal layer. Stratum corneum contains
mature keratinocytes which produce fibrous proteins namely keratins (Kelly
and Taylor. 2009). This layer has a protective role against most foreign
substances and fluid loss from the body. Most of the cells in the epidermis are
keratinocytes that originate from basal layer, which is the deepest layer of the
epidermis. The skin color is relevant to the melanocyte cells, which are located
in epidermis as well (Kelly and Taylor. 2009).
9Figure 2.1 Structural layers of skin - epidermis, the dermis and subcutis (adapted
from http://bioserv.fiu.edu/~walterm/FallSpring/Integument/integument_ex1_review.htm)
Dermis, the middle layer of skin contains blood and lymph vessels, hair
follicles, sweat glands, collagen bundles, fibroblasts and nerves. Dermis has a
vascular structure composed of collagen, elastin, and ground substanc, and
various glands. Dermis cells originate from primitive mesenchymal cells,
including fibroblasts and several other cells such as histiocytes, mastocytes,
lymphocytes, plasma cells, and eosinophils. Fibroblast cells produce collagen,
elastin, and matrix. Dermis is known with multinucleated and large fibroblasts
cells. Black ethnicities have shown the highest rate of keloid and interestingly
have larger fibroblasts with more than two nucleuses in the skin (Montagna
and Carlisle, 1991).
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It has been known that there is a difference between structure and the function
of the skin among various ethnicities (Kelly and Taylor, 2009). Most of
studies had their focus on the thickness, density and compactness of the
stratum corneum between the different races (Table 2.1). Difference in the
skin structure and consequently susceptibility to the skin disorders could be
the result of difference in both genetic and environmental factors. In the
following table 2.1, the major differences between dermal structures of black
and white skin have been summarized.
Table 2.1 Comparison of dermal structures between Black and White skins
White skin Black skin
Dermis Thin and less compact Thick and compact
Papillary and reticular layer More distinct Less distinct
Collagen fiber bundles Large Small, close stacking
Fiber fragments Sparse Prominent and numerous
Melanophages Few Numerous and larger
Lymphatic vessels Moderate, dilated Dilated empty channels
Fibroblasts Few Numerous and larger,
binucleated and
multinucleated
Elastic fibers Several, elastosis Few, elastosis uncommon
Superficial blood vessel Sparse to moderate Numerous, mostly dilated
Glycoprotein Variable Numerous in the dermis
(Adapted from Kelly and Taylor. 2009)
In addition, dermis is more susceptible to develop keloid (Taylor, 2002).
Hence, keloid is called a benign dermal fibroproliferative tumor with plenty of
extracellular matrix (ECM) proteins, which result in overabundance of
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collagen formation (Bayat and McGrouther, 2006, Kose and Waseem, 2008).
Hence, keloid is also called as collagenous tumors of the dermis that form
during a prolonged wound-healing process, because, large amount of scar
tissue grow out from the wound site, and consequently cause an increase of
collagen production and decrease in collagen lysis.
The subcutis is the deepest layer of skin, which contains a network of collagen
and fat cells. It has a mechanical and thermal protection role and serves as
energy storage. During skin injury, both skin cells and fibroblast cells begin
multiplying to repair the damage. Fibroblast cells provide a network for skin
cells to migrate to the injured area to repair the wound (Singer and Clark,
1999). There is a balance between proliferation of fibroblast and skin cells in
repairing the wound. In normal skin, the skin cells proliferate faster than
fibroblast cells and the wound will be repaired as usual. In keloid after wound
healing, fibroblast cells continue to replicate and form a large scar tissue
around the wound (Singer and Clark, 1999). In general, keloid forms if
wound-healing processes become prolonged. Alterations in the cellular signals
that control growth and proliferation could be the related to the process of
keloid formation. It has been known that several growth factors including
epidermal growth factors (EGF), transforming growth factors (TGF) and their
receptors and downstream proteins play a critical role in keloid formation.
2.2 Wound healing and the role of TGFΒ1
Wound healing has been known to be a dynamic, interactive process, in which
several factors such as soluble mediators, blood cells, extracellular matrix, and
parenchymal cells are involved (Singer and Clark, 1999).
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In addition, three overlapping phases of inflammation, tissue formation
(proliferation) and tissue remodeling has been characterized in wound healing.
Immediately after injury, coagulation system triggers a cascade of downstream
processes that result in inflammation such as clotting cascade, vasoconstriction
and vasodilation, polymorphonuclear neutrophils, macrophages, and decline of
inflammatory phase (Singer and Clark, 1999). Without inflammation, wound
healing never happens. During inflammation, the movement of plasma and
leukocytes from the blood into the injured tissues increase (Figure 2.2). Innate
immune system has a critical role in the initial stages of inflammation.
Coagulation process is a critical part of body homeostasis in which injured
blood vessels covered by a platelet and fibrin-containing clot to
stop bleeding, and begin repair of the damaged vessel and subsequently wound
healing. A complex interplay between several growth factors and mediators
trigger this process. Platelets secrete several mediators of wound healing, such
as platelet-derived growth factor (PDGF) and TFGβ1 that activate the
fibroblast cells (Singer and Clark, 1999). In addition, activated macrophages
secrete several growth factors such as TGFβ1, TGFA, FGF, PDGF and VEGF
in order stimulate the fibroblast cells of dermis and wound vascularization
(Figure 2.2). Macrophage and monocyte cells play a pivotal role in
inflammation, such that their secreted growth factors are most important in
wound repair. Macrophage depleted animals show an impaired wound healing
(Leibovich and Ross, 1975). Inflammation stage, TGFβ family members are
mainly secreted by macrophages and platelets, in which TFGβ1 and 2 play a
role in epidermal-cell motility, chemotaxis of macrophages and fibroblasts,
extracellular matrix synthesis and remodeling, while TGFβ3, that is mainly
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secreted by macrophage cells play an anti-scarring role (Singer and Clark,
1999). Approximately two or three days after injury, before ending up the
inflammation phase, wound re-epithelialization (proliferation) phase begins
with entry of fibroblast cells into the wound site (Falanga, 2005) (Figure 2.3).
Figure 2.2 Inflammatory phase of wound in day 3 which has been triggered
by several cytokines (Adapted from Cutaneous wound healing. Singer  and
Clark, 1999)
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Figure 2.3 Approximate times of the different phases of wound healing
(Adapted from http://en.wikipedia.org/wiki/Wound_healing#cite_note-7)
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This phase also includes several overlapping stages such as angiogenesis, fibroplasia and
granulation tissue formation, collagen deposition, epithelialization and contraction
(Figure 2.3). Cell migration, proliferation and angiogenesis are major processes of this
phase; therefore digestion of clot is necessary to allow cells to migrate. Hence, several
proteinases such as collagenases [collagenase 1 (MMP-1), gelatinase A (MMP-2),
stromelysin 1 (MMP-3), and collagenase 3 (MMP-13)] and plasminogen activator
[urokinase-type plasminogen activator (u-PA) and tissue plasminogen activator (t-PA)]
are needed to digest basement membrane and ECM (Figure 2.4).  Most of these enzymes
such as plasminogen activator, collagenases, gelatinase A, and stromelysin secreted by
fibroblast cells facilitate the cell migration (Singer and Clark, 1999).
Angiogenesis occurs along with fibroblast proliferation. When the migration of cells
facilitates, fibroblast cells enter into the wound site and at the end of first week,
fibroblasts are the major cells in the wound site which is called fibroplasia (Stadelmann
et al., 1998). Growth factors, especially PDGF and TGFβ1 concurrently with
extracellular matrix molecules are important to stimulate fibroblast proliferation from
adjacent tissue towards the wound area (Adam et al., 1999). Collagen production is one
of the important roles of fibroblast cells in this stage of wound healing and subsequently,
the temporary extracellular matrix gradually substitutes with a collagenous matrix,
perhaps as a result of the action of TGFβ1 (Singer and Clark, 1999).
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Figure 2.4 Pathway and major molecules that are involved in re-epithelialization and
neovascularization at day 5. (Adapted from Cutaneous wound healing. Singer and Clark,
1999)
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With enough amount of collagen, fibroblast cells stop collagen production and cells
undergo apoptosis. Cell apoptosis disruption at this stage occurs in fibrotic disorders
such as keloid (Singer and Clark, 1999).
Fetal skin reepithelializes more quickly than adult skin and fetal wound never produces
scarring (Singer and Clark, 1999). Fetal skin is enriched with metalloproteinases and is
poor in TGFβ1 (O'Sullivan et al., 1996, Bullard et al., 1997). In addition, evidence
showed that down regulation of TGFβ1 reduces the scarring in adult rats (Shah et al.,
1995) and adding TGFβ1 to the fetal skin stimulates the development of scarring
(O'Sullivan et al., 1996). Therefore, lack of scarring in fetal skin has been attributed to
the small amounts of TGFβ1 in the fetal skin (Singer and Clark, 1999).
2.3 Keloid and hypertrophic scar
Keloid and hypertrophic scars are most common fibrotic disorders which are due to
extra production of collagen within the wound. Keloid and hypertrophic scar disorders
occur usually after trauma, inflammation, surgery and burns. There are significant
differences at both clinical and histological level between hypertrophic and keloid scars
(Tables 2.2 and 2.3). Hypertrophic scars are confined to the wound area and never
extend from the wound site. While in contrast, keloid scars are not restricted to the
wound site and grow around the wound area (Plates 2.1 and 2.2).
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Plate 2.1 Keloid (Photo with permission, see appendix B, attachment 2)
Plate 2.2 Hypertrophic scar (Photo with permission, see appendix B, attachment 2)
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Table 2.2 Clinical differences of keloid and hypertrophic scars
Hypertrophic Scars Keloid
Develop 4-8 weeks after surgery May develop up to several years after
the injury
Usually regress over the time Rarely regress with time
Do not extend beyond the initial site
of injury
Spread outside the boundaries of the
initial lesion
Occur when scars cross joints or skin
creases at a right angle
Occur predominantly on the ear lobe,
shoulders, sternal notch, rarely
develop across joints
Improve with appropriate surgery Often worsened by surgery
Frequent incidence Rare incidence
Have no association with skin color Associated with dark skin color
40% to 70% following surgery, up to
91% following surgery
6% to 16% in African populations
Mostly on shoulders, neck,
presternum, knees and ankles
Mostly on anterior chest, shoulders,
earlobes, upper arms and cheeks
Low recurrence rates after excision
of the original hypertrophic scar
High recurrence rates following
excision
Adapted from (Wolfram et al., 2009, Gauglitz et al., 2011)
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Table 2.3 Histological features of keloid and hypertrophic scars
Hypertrophic scar Keloid
Primarily fine, well-organized, wavy
type III collagen bundles oriented
parallel to epidermis surface with
abundant nodules containing
myofibroblasts and plentiful acidic
mucopolysaccharide.
Disorganized, large, thick, type I and
III hypocellular collagen bundles with
no nodules or excess myofibroblasts.
Large extracellular collagen filaments Pale-staining hypocellular
collagen bundles with no nodules or
excess myofibroblasts
Plentiful acidic mucopolysaccharides Poor vascularization with widely
scattered dilated blood vessels.
Proliferating cell nuclear antigen
(PCNA)/p53-level/ATP expression low
PCNA/p53-level/ATP expression high
Adapted from (Gauglitz et al., 2011)
In addition, keloid and hypertrophic scars have significant differences at histological
level as well. From histological viewpoint, both hypertrophic and keloid scars contain a
large amount of collagen (Gauglitz et al., 2011).
Keloid and hypertrophic scars have shown an equal sex distribution (Gauglitz et al.,
2011). The frequency of hypertrophic scar is estimated within 40-70% after surgery and
up to 90% after burn. (Deitch et al., 1983, Lewis and Sun, 1990) The genetic issue is
more applicable for keloid and a study showed that approximately 50% of keloid
patients had a positive family history of keloid (Bayat et al., 2005a).
21
2.4 Evidence for the role of genetics in keloid
Several evidences have also shown that genetics play a critical role in keloid formation.
Familial aggregation, occurrence in identical twins, Mendelian disorders, expression
studies and high prevalence of keloid among different ancestries provide strong evidence
in favor of genetic factors in keloid formation. Keloid is a complex condition in which
several genetic and environmental factors could play a role in the disease formation
(Figure 2.5). Evidence for the role of genetic factors emerged through several
independent studies on populations with different ethnic backgrounds.
Figure 2.5 Genetic and environmental risk factors contributing to the development of
keloid (Adapted from Shih and Bayat, 2010).
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The incidence of keloid is different among populations reflecting different etiologic
factors. Keloid is 5-15 folds more common among black people compared to white
people (LeFlore, 1980). Keloid scar is the fifth most common skin disease in black adult
patients in United Kingdom (Child et al., 1999). Keloid is most common in Chinese
population in Asia (Alhady and Sivanantharajah, 1969). Evidence for the role of genetic
factors emerged through families that had higher frequency to develop keloid and
identical twins and expression studies.
2.4.1 Evidence from families with keloid
Approximately one-third of keloid probands have first-degree relatives with keloid.
Many reports have been published on cases with familial keloid (Bayat et al., 2003b,
Marneros and Krieg, 2004, Chen et al., 2006b, Bella et al., 2011) most probably
reflecting the importance of genetic factors among these families. Occurrence of familial
keloid was reported as 1.9% (19 out of 1000) among South Indians (Ramakrishnan et
al., 1974).
In an analysis conducted on fourteen families with familial keloid from different
ethnicities including African American (n = 10), Japanese (n = 2), white (n = 1) and
African Caribbean (n = 1), it was found to have an autosomal dominant mode of
inheritance with incomplete penetrance and variable expression (Marneros et al., 2001)
.Among these, families with three to sixteen affected members have been seen. Bayat et
al., (2003a) described three cases with black Jamaican origin who had familial keloid
scar. Furthermore, two large multigenerational families with Japanese and African-
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American ancestries have been described in a genome-wide linkage study with an
autosomal dominant inheritance of keloid (Marneros et al., 2004). Another study
reported familial keloid in six Han Chinese families that have shown autosomal
dominant inheritance pattern with incomplete clinical penetrance and variable
expression (Chen et al., 2006a). Family history of keloid was reported in eight cases in a
clinical examination of eleven Nigerian women with hypertrophic/keloidal lesions of the
breast (Olasod, 2010). In another study, it has been reported to have autosomal recessive
inheritance pattern in 34 Nigerian keloid families (Omo-Dare, 1975). More recently, 38
nuclear black families from Sudan have been reported who had familial keloid scars
(Bella et al., 2011).Keloid is a heterogeneous disease at both clinical and genetic level
with a variable clinical expressivity between families and within the affected members
of same family (Marneros et al., 2001, Marneros et al., 2004, Bella et al., 2011).In
general, an autosomal dominant mode of inheritance with incomplete penetrance and
variable expressivity is well reported for keloid.
2.4.2 Evidence from identical twins with keloid
The presence of identical twins with keloid strongly supports the role of genetic risk
factors in keloid formation. Marneros et al., (2001) found four families with identical
twins. All twins, developed keloids with a dominant inheritance pattern in African
American population. Ramakrishnan et al. (1974) and Jacobson (1948) described a pair
of twins with keloid formation in South India.
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2.4.3 Evidence from Mendelian disorders with keloid
Several Mendelian disorders manifest keloid as part of clinical features. There is a
possibility that individuals with a connective-tissue disorder develop keloid as part of
the disease (Table 2.4). Almost all Mendelian syndromic forms of keloid have shown a
dominant mode of inheritance which is consistent with the mode of inheritance among
families with non-syndromic keloid (Table 2.4).
Rubinstein-Taybi syndrome1 (RSTS1) develop keloid in a high frequency. RSTS1 is
caused by a contiguous gene deletion involving the CREBBP gene as well as other
neighboring genes on the chromosome 16p13.3 (OMIM # 180849). In a questionnaire-
based study on 61 adults with RSTS ranging in age from 18 to 67 years, Stevens et al.
(2011) found that 57% of patients developed keloid. Siraganian et al. (1989) also
detected keloid in 28 patients out of 574 individuals with RSTS. High incidence of
keloid as a proliferative disorder and neoplasms in RSTS patients attributed to the
function of CREBBP in cAMP-regulated cell immortalization (Petrij et al., 1995).
